skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Combined modality radioprotection: the use of glucan and selenium with WR-2721

Technical Report ·
OSTI ID:6262662

Recent radiation accidents at Chernobyl (U.S.S.R.) and at Goiania (Brazil) have again focused attention on the potential value of agents that could mitigate the biological effects of radiation exposure. Such agents, commonly called radioprotectants, could be valuable not only for individuals whom may be exposed to radiation during accident rescue and/or clean-up activities, but also for astronauts who may be subjected to predictable radiation exposures, and for individuals undergoing radiotherapy. During the past several decades, studies of numerous radioprotective agents have led to the realization that not all radioprotectants mitigate damage through similar mechanisms. Because various radioprotective agents differ in mechanisms of action and in optimal administration of action and in optimal administration times with respect to radiation exposure, the use of multiple agents may in some instances provide significantly better protection than single agents. In the studies described here, combinations of such agents were administered to mice and evaluated for effects on survival enhancement and on hemopoietic recovery. By design, individual agents were used at doses that induce minimal-to-no toxic or performance-degrading side effects.

Research Organization:
Armed Forces Radiobiology Research Inst., Bethesda, MD (USA)
OSTI ID:
6262662
Report Number(s):
AD-A-227554/3/XAB; AFRRI-SR-90-20
Resource Relation:
Other Information: Pub. in International Jnl. of Radiation Oncology, Biology, Physics, Vol. 18, No. 5, 1069-1075(May 1990)
Country of Publication:
United States
Language:
English